• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Cabaletta Bio Inc.

    3/31/25 8:33:10 AM ET
    $CABA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CABA alert in real time by email
    S-8 1 caba-s8-mar-2025.htm S-8 S-8

    As filed with the Securities and Exchange Commission on March 31, 2025

    Registration No. 333-  

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    FORM S-8

    REGISTRATION STATEMENT

    Under

    The Securities Act of 1933

    CABALETTA BIO, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

     

    Delaware

    82-1685768

    (State or other jurisdiction of

    incorporation)

    (I.R.S. Employer

    Identification No.)

     

     

     

    2929 Arch Street, Suite 600

    Philadelphia, PA

    19104

    (Address of principal executive offices)

    (Zip Code)

    Cabaletta Bio, Inc. 2019 Stock Option and Incentive Plan

    (Full title of the plan)

    Steven Nichtberger

    President and Chief Executive Officer

    Cabaletta Bio, Inc.

    2929 Arch Street, Suite 600

    Philadelphia, PA 19104

    (267) 759-3100

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

     

     

     

     

     

     

    Large accelerated filer

    ☐

    Accelerated filer

    ☐

     

     

     

     

    Non-accelerated filer

    ☒

    Emerging growth company

    ☐

     

     

     

     

     

     

    Smaller reporting company

    ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

     

    STATEMENT OF INCORPORATION BY REFERENCE

    This Registration Statement on Form S-8 is filed to register the offer and sale of an additional 2,029,724 shares of the Registrant’s common stock, $0.00001 par value per share, to be issued under the Registrant’s 2019 Stock Option and Incentive Plan. This Registration Statement incorporates by reference the contents of the registration statements on Form S-8, File No. 333-234367, filed by the Registrant on October 29, 2019, File No. 333-237484, filed by the Registrant on March 30, 2020, File No. 333-254342, filed by the Registrant on March 16, 2021, File No. 333-263637, filed by the Registrant on March 17, 2022, File No. 333-270595, filed by the Registrant on March 16, 2023, File No. 333-273863, filed by the Registrant on August 10, 2023 and File No. 333-278124, filed by the Registrant on March 21, 2024, and the registration relating to the Registrant’s 2019 Stock Option and Incentive Plan and 2019 Employee Stock Purchase Plan pursuant to General Instruction E.

    Part II

    Information Required in the Registration Statement

     

     

     

    Item 8.

    Exhibits

    Refer to the Exhibit Index on the next page for a list of exhibits filed as part of this registration statement, which Exhibit Index is incorporated herein by reference.

    EXHIBIT INDEX

     

     

     

    Exhibit
    No.

    Description of Exhibit

     

     

     4.1

    Third Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect (Incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019).

     

     

     4.2

    Amended and Restated Bylaws (Incorporated by reference to Exhibit 3.2 of the registrant’s Current Report on Form 8-K (File No. 001-39103) filed on October 30, 2019).

     

     

     4.3

    Amendment No. 1 to the Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-39103) filed with the SEC on May 12, 2022).

     

     

     4.4

    Description of Securities (incorporated by reference to Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K (File No. 001-39103) filed with the Securities and Exchange Commission on March 21, 2024).

     

     

     5.1*

    Opinion of Goodwin Procter LLP.

     

     

    23.1*

    Consent of Ernst & Young, Independent Registered Public Accounting Firm.

     

     

    23.2*

    Consent of Goodwin Procter LLP (included in Exhibit 5.1).

     

     

    24.1*

    Power of Attorney (included on signature page).

     

     

    99.1

    2019 Stock Option and Incentive Plan, and forms of award agreements thereunder (Incorporated by reference to Exhibit 10.2 to the registrant’s Registration Statement on Form S-1, as amended (File No. 333-234017) filed with the SEC on October 16, 2019).

     

     

    99.2

    2019 Employee Stock Purchase Plan (Incorporated by reference to Exhibit 10.3 to the registrant’s Registration Statement on Form S-1, as amended (File No. 333-234017) filed with the SEC on October 16, 2019).

     

     

    107*

    Filing Fee Table.

    *

    Filed herewith.

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Philadelphia, Commonwealth of Pennsylvania, on this 31st day of March, 2025.

     

     

     

    CABALETTA BIO, INC.

     

     

    By:

    /s/ Steven Nichtberger

     

    Steven Nichtberger, M.D.

     

    President and Chief Executive Officer

    POWER OF ATTORNEY AND SIGNATURES

    KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Steven Nichtberger and Anup Marda as such person’s true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person’s name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following person in the capacities and on the date indicated.

     

     

     

     

     

    Name

    Title

    Date

     

     

     

    /s/ Steven Nichtberger

    Steven Nichtberger, M.D.

    President, Chief Executive Officer and Director

    (Principal Executive Officer)

    March 31, 2025

     

     

     

    /s/ Anup Marda

    Anup Marda

    Chief Financial Officer

    (Principal Financial Officer and Principal Accounting Officer)

    March 31, 2025

     

     

     

    /s/ Catherine Bollard

    Catherine Bollard, M.D.

    Director

    March 31, 2025

     

     

     

    /s/ Scott C. Brun

    Scott C. Brun, M.D.

    Director

    March 31, 2025

     

     

     

    /s/ Richard Henriques

    Richard Henriques

    Director

    March 31, 2025

     

     

     

    /s/ Mark Simon

    Mark Simon

    Director

    March 31, 2025

     

     

     

    /s/ Shawn Tomasello

    Shawn Tomasello

    Director

    March 31, 2025

     

     


    Get the next $CABA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CABA

    DatePrice TargetRatingAnalyst
    12/20/2024$15.00 → $6.00Outperform → In-line
    Evercore ISI
    12/19/2024$12.00 → $6.00Overweight → Equal Weight
    Wells Fargo
    10/10/2024$10.00Buy
    UBS
    2/5/2024$36.00Buy
    Jefferies
    11/29/2023$38.00Outperform
    William Blair
    10/24/2023$40.00Overweight
    Cantor Fitzgerald
    10/19/2023$31.00Buy
    Stifel
    9/5/2023$22.00Buy
    Citigroup
    More analyst ratings

    $CABA
    Leadership Updates

    Live Leadership Updates

    See more
    • Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors

      – Ms. Tomasello created and led global commercial and medical affairs functions at Kite Pharma from pre-launch through its acquisition by Gilead Sciences – PHILADELPHIA, July 24, 2023 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello has over 35 years of experience in the life sciences industry, including specific expertise in CD19-CAR T therapy, where she most recently served as the Chief Commercial Officer of Kite Pharma, Inc. between 20

      7/24/23 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors

      Dr. Brun also appointed as Chairperson of Jasper Research and Development Committee and to Compensation Committee Board member Vishal Kapoor appointed to Jasper Audit and Compensation Committees REDWOOD CITY, Calif., June 20, 2023 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ:JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced the appointment of Scott Brun, M.D., to Jasper's Board of Directors. Dr. Bru

      6/20/23 8:00:00 AM ET
      $CABA
      $FBRX
      $JSPR
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cabaletta Bio Announces Appointment of Michael Gerard as General Counsel

      PHILADELPHIA, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Michael Gerard has been appointed general counsel. "We are very pleased to welcome Mike to the executive team. His experience with a wide range of strategic legal and corporate matters within the life sciences industry will complement the management team as we advance clinical development for DSG3-CAART in our DesCAARTes™ trial, and further develop follow-on candidates from our deep pipeline of precision therapies for pati

      9/7/21 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cabaletta Bio downgraded by Evercore ISI with a new price target

      Evercore ISI downgraded Cabaletta Bio from Outperform to In-line and set a new price target of $6.00 from $15.00 previously

      12/20/24 7:29:05 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Cabaletta Bio from Overweight to Equal Weight and set a new price target of $6.00 from $12.00 previously

      12/19/24 7:31:17 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • UBS initiated coverage on Cabaletta Bio with a new price target

      UBS initiated coverage of Cabaletta Bio with a rating of Buy and set a new price target of $10.00

      10/10/24 7:27:43 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    SEC Filings

    See more
    • Cabaletta Bio Inc. filed SEC Form 8-K: Leadership Update

      8-K - Cabaletta Bio, Inc. (0001759138) (Filer)

      5/19/25 5:22:45 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Cabaletta Bio Inc.

      10-Q - Cabaletta Bio, Inc. (0001759138) (Filer)

      5/15/25 7:10:42 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Cabaletta Bio, Inc. (0001759138) (Filer)

      5/15/25 7:05:04 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CABA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $CABA
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CABA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $CABA
    Financials

    Live finance-specific insights

    See more
    • SEC Form 4 filed by Director Brun Scott C.

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      5/19/25 9:44:32 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by President & CEO Nichtberger Steven

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      5/19/25 9:40:08 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by General Counsel Gerard Michael

      4 - Cabaletta Bio, Inc. (0001759138) (Issuer)

      5/19/25 9:39:33 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

      PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 11:05 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company's website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (NASDAQ:CABA) is a clinical-stage bio

      5/29/25 8:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts

             – Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. patients with no approved treatments other than monthly IVIg – – Multiple Phase 1/2 disease cohorts fully enrolled across the RESET™ clinical development program; 44 patients enrolled and 23 patients dosed as of May 9, 2025 – – SLE and LN registrational discussions with FDA anticipated in 3Q25; systemic sclerosis registrational discussions with FDA anticipated in 4Q25 – – New clinical data on rese-cel in myositis, SLE / LN and systemic sclero

      5/15/25 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

      – FDA meeting to align on myositis registrational trial designs for rese-cel in 1H25 on track – – Enrolling approximately one patient per week across the RESET™ clinical development program since ACR Convergence presentation in November 2024 with 33 patients enrolled across 56 active clinical trial sites in the U.S. & Europe as of March 14, 2025 – – Clinical and translational data on rese-cel to be presented in three oral presentations at the EULAR 2025 Congress in June – – Operational runway into 1H26 with cash and cash equivalents of $164.0 million as of December 31, 2024 – PHILADELPHIA, March 31, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a clinical-stage bi

      3/31/25 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/6/24 4:05:57 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/5/24 4:50:19 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Cabaletta Bio Inc.

      SC 13G/A - Cabaletta Bio, Inc. (0001759138) (Subject)

      12/5/24 3:36:55 PM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

      – CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight patients and one previously reported ICANS event – – Compelling clinical responses observed in lupus and myositis patients with up to six months of follow-up; first SSc patient demonstrated an emerging, drug-free clinical response – – All eight patients with active, refractory autoimmune disease discontinued all immunosuppressants prior to CABA-201 infusion and through the follow-up period – – Consistent and complete B cell depletion observed in all patients within the first month after CABA-201 infusion; evidence of transitional naïve B cell repopula

      11/18/24 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

      – Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash

      11/14/24 7:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

      – No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both patients by day 15 post-infusion – – Improvements in both patients' specific disease measures, consistent with academic experience of a similar 4-1BB CD19-CAR T, suggest emerging clinical benefit with CABA-201 while discontinuing all disease-specific therapies other than a planned steroid taper in one patient – – Immature, naïve B cell repopulation in first IMNM patient observed at week 8 consistent with a potential immu

      6/14/24 2:00:00 AM ET
      $CABA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care